Cost Effectiveness of Clozapine and Risperidone in "Revolving Door" Schizophrenia

재발과 입원을 반복하는 만성 정신분열병 환자에서 비전형적 항정신병약물의 비용-효과

  • Nam, Jong-Won (Kunsan Mental Health Center) ;
  • Lee, Min-Soo (Department of Neuropsychiatry, College of Medicine, Korea University) ;
  • Jeong, In-Kwa (Department of Neuropsychiatry, College of Medicine, Korea University) ;
  • Kwak, Dong-Il (Department of Neuropsychiatry, College of Medicine, Korea University)
  • 남종원 (군산시 정신보건센터) ;
  • 이민수 (고려대학교 의과대학 신경정신과학교실) ;
  • 정인과 (고려대학교 의과대학 신경정신과학교실) ;
  • 곽동일 (고려대학교 의과대학 신경정신과학교실)
  • Published : 2000.12.31

Abstract

Objectives : Risperidone and clozapine belong to a new generation of antipsychotics that are reportedly more effective and better tolerated than conventional neuroleptics. However, each of these agents costs far more per unit than conventional neuroleptics. The purpose of our retrospective study was to ascertain the total cost and effectiveness of treatment before and after administration of risperidone and clozapine in "revolving door" schizophrenia patients. Method : Data collected on revolving door schizophrenics for 2 years before clozapine and risperidone treatment and for at least 2 years after clozapine and risperidone treatment. Direct cost of inpatient and outpatient treatment was measured. Effectiveness was scaled as "years of mild disability gained". Result : Both risperidone and cloazpine result in higher costs and additional benefits to patients, for example, increased mild disability, reduced number of relapse, and reduced hospital length-of-stay. An ICER of risperidone was less than Rc and ICER of clozapine was greater than Rc. According to decision-analytic this model, risperidone had favorable cost-effectiveness ratios relative to clozapine. Conclusion : We have assumed that risperidone is more cost-effective than clozapine.

Keywords